Shopping Cart 0
Cart Subtotal
USD 0

Alzheimers Disease: Competitive Landscape to 2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3495

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 6990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10485
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Alzheimer's Disease: Competitive Landscape to 2026

Summary

Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The degeneration of neurons starts in the brainstem before progressing to the hippocampus, frontal lobe, amygdala, parietal lobe, and temporal lobe. The cause of AD is unknown, but it appears to be multifactorial, with most research aimed at the A? peptides and tau proteins. The irregular clearance and metabolism of these proteins are likely contributors to the presentation of the disease. The risk of developing AD is believed to be determined by a combination of genetic, metabolic, behavioral, and environmental factors.

This report provides an assessment of the pipeline, clinical, and commercial landscape of AD. Overall, GlobalData expects new drug approvals to drive AD market growth over the next decade (2016-2026).

Scope

- This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include-

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

- Commercial Assessment: leading marketed products, current and future players

- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global AD market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

READ MORE

Table Of Content

Scope

Table of Contents

1. Preface 2

1.1 Table of Contents 2

1.2 Abbreviations 3

1.3 Related Reports 4

1.4 Upcoming Related Reports 5

2. Executive Summary 6

2.2 Key Findings 7

2.2 Key Events 8

3. Introduction 9

3.1 Report Scope 10

3.2 Disease Overview and Epidemiology 12

4. Pipeline Assessment 15

4.1 Pipeline Overview 16

4.2 Pipeline Breakdown by Region/Country 18

4.3 Pipeline Breakdown by Molecule Type and Target 19

4.4 Drug Review Designations 20

4.5 Products in Clinical Development 21

5. Clinical Trial Assessment 23

5.1 Clinical Trials Overview 24

5.2 Top Sponsors of Clinical Trials in AD 25

5.3 Trial Breakdown by Region 27

5.4 Therapy Area Perspective 28

5.5 Enrollment Analytics 29

6 Commercial Assessment 32

6.1 Leading Marketed Products 33

6.2 Current & Future Players 34

7. Competitive Landscape Analysis (2016-2026) 35

7.1 Events Classification Overview 36

7.2 US 37

7.3 5EU 38

7.4 Japan 39

7.5 China 40

8 Appendix 42

8.1 Sources 43

8.2 Methodology 45

8.3 Key Events Included in the Analysis 46

8.4 About the Authors 47

8.5 About GlobalData 50

8.6 Disclaimer 52

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Biogen

Eisai Co.

F. Hoffmann-La Roche

Otsuka Pharmaceuticals

Eli Lilly

Ionis Pharmaceuticals

TauRx Therapeutics

Axsome Therapeutics

Accera

Novartis

AZTherapies

AB Science

Grifols

Shanghai Green Valley Pharmaceutical

Archer Pharmaceuticals

Changchun Huayang High-Tech

Intra-Cellular Therapies

Avanir Pharmaceuticals

Promis Neurosciences

Pfizer

Johnson & Johnson

AstraZeneca

Janssen

Allergan

Adamas Pharmaceuticals

Lundbeck

Merz Pharma GmbH

Icure Pharmaceutical

Shire

Chase Pharmaceuticals

Alzheimer's Disease: Competitive Landscape to 2026

Summary

Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The degeneration of neurons starts in the brainstem before progressing to the hippocampus, frontal lobe, amygdala, parietal lobe, and temporal lobe. The cause of AD is unknown, but it appears to be multifactorial, with most research aimed at the A? peptides and tau proteins. The irregular clearance and metabolism of these proteins are likely contributors to the presentation of the disease. The risk of developing AD is believed to be determined by a combination of genetic, metabolic, behavioral, and environmental factors.

This report provides an assessment of the pipeline, clinical, and commercial landscape of AD. Overall, GlobalData expects new drug approvals to drive AD market growth over the next decade (2016-2026).

Scope

- This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include-

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

- Commercial Assessment: leading marketed products, current and future players

- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global AD market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

READ MORE

Scope

Table of Contents

1. Preface 2

1.1 Table of Contents 2

1.2 Abbreviations 3

1.3 Related Reports 4

1.4 Upcoming Related Reports 5

2. Executive Summary 6

2.2 Key Findings 7

2.2 Key Events 8

3. Introduction 9

3.1 Report Scope 10

3.2 Disease Overview and Epidemiology 12

4. Pipeline Assessment 15

4.1 Pipeline Overview 16

4.2 Pipeline Breakdown by Region/Country 18

4.3 Pipeline Breakdown by Molecule Type and Target 19

4.4 Drug Review Designations 20

4.5 Products in Clinical Development 21

5. Clinical Trial Assessment 23

5.1 Clinical Trials Overview 24

5.2 Top Sponsors of Clinical Trials in AD 25

5.3 Trial Breakdown by Region 27

5.4 Therapy Area Perspective 28

5.5 Enrollment Analytics 29

6 Commercial Assessment 32

6.1 Leading Marketed Products 33

6.2 Current & Future Players 34

7. Competitive Landscape Analysis (2016-2026) 35

7.1 Events Classification Overview 36

7.2 US 37

7.3 5EU 38

7.4 Japan 39

7.5 China 40

8 Appendix 42

8.1 Sources 43

8.2 Methodology 45

8.3 Key Events Included in the Analysis 46

8.4 About the Authors 47

8.5 About GlobalData 50

8.6 Disclaimer 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Biogen

Eisai Co.

F. Hoffmann-La Roche

Otsuka Pharmaceuticals

Eli Lilly

Ionis Pharmaceuticals

TauRx Therapeutics

Axsome Therapeutics

Accera

Novartis

AZTherapies

AB Science

Grifols

Shanghai Green Valley Pharmaceutical

Archer Pharmaceuticals

Changchun Huayang High-Tech

Intra-Cellular Therapies

Avanir Pharmaceuticals

Promis Neurosciences

Pfizer

Johnson & Johnson

AstraZeneca

Janssen

Allergan

Adamas Pharmaceuticals

Lundbeck

Merz Pharma GmbH

Icure Pharmaceutical

Shire

Chase Pharmaceuticals